Using donor T cells to treat cancer patients with BK and JC viruses

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase II trial investigates the effectiveness of donor-derived cytotoxic T lymphocytes in treating patients with malignancies affected by BK and/or JC viruses. The study focuses on patients with various cancers, HIV/AIDS, or those with a history of solid organ transplants who are experiencing BK or JC infections. Participants will receive intravenous infusions of HLA-matched BK-specific cytotoxic T lymphocytes, with the possibility of additional infusions based on their response. The trial aims to evaluate the safety, efficacy, and persistence of these T cells in the patient's system over a 12-month follow-up period.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients ≥ 2 years.
* English and non-English speaking patients are eligible.
* Immunocompromised patients including but not limited to those with any type of malignancy, HIV/AIDS, or history of solid organ transplant
* Non-immunocompromised patients with PML/JC virus encephalitis
* Microscopic or greater hematuria urine or blood PCR positive for BK virus
* Biopsy proven BK nephritis and urine or blood PCR positive for BK virus disease and/or polyomavirus.
* Definite or probable PML/JC viral encephalitis (see Appendix C)
* JC end-organ disease
* Receiving \> 6 mg / day of prednisone or equivalent at the time of enrollment.
* Patients with BK virus hemorrhagic cystitis, who are receiving treatment with cidofovir, leflunomide, or other antiviral therapy with no response, will be eligible for CTL infusion.
* Patients with JCV encephalitis / PML may be receiving pembrolizumab.
* Written informed consent and/or signed assent from patient, parent or guardian.
* Patients with cognitive impairments are eligible.
* A negative pregnancy test in female patients of childbearing potential. Childbearing potential is defined as pre-menopausal, post-menopausal for \< 1 year, and not having undergone surgical sterilization.
* Women of childbearing potential must be willing to use an effective contraceptive measure while on study.
* Patients enrolled on this study may be enrolled on other IND studies at the discretion of the PI.
* Patients with bacterial infections must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to enrollment.
* Patients with fungal infections patients must be receiving definitive systemic anti fungal therapy and have no signs of progressing infection for 1 week prior to enrollment.
* Patients may be re-enrolled in the protocol if the BK or JC virus infection recurs, so long as they meet all the other eligibility criteria at the time of re-enrollment.

Exclusion Criteria:

* Patients receiving \> 6 mg / day of prednisone or equivalent at time of
* Patients who have received ATG within 14 days of enrollment
* Patients who have received donor lymphocyte infusion (DLI) within 28 days of enrollment.
* Patients who have received alemtuzumab within 28 days of enrollment.
* Patients with other uncontrolled infections (including HIV/AIDS). Uncontrolled infection is defined as the presence of hemodynamic instability attributable to sepsis, or new symptoms, worsening physical signs, or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as uncontrolled infection.
* Patients with active acute GVHD grades II-IV.

Where it's running

• M D Anderson Cancer Center
  Houston, Texas, United States Recruiting

Study contacts

• Principal investigator: George Chen, MD — M.D. Anderson Cancer Center
• Study coordinator: George Chen, MD
• Email: GLChen1@mdanderson.org
• Phone: 713-792-3630

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MK-2010 with Sac-TMT in advanced solid tumors

  This study tests MK-2010 combined with sacituzumab tirumotecan (sac-TMT) to see if it can help people with advanced solid tumors.

  Recruiting at 4 sites Phase 2 Merck Sharp & Dohme LLC · San Antonio, Texas and 3 other locations · NCT07785609

• Belzutifan in adolescents with solid tumors

  This study tests belzutifan in teenagers whose solid tumors can't be removed by surgery or have spread.

  Recruiting at 10 sites Phase 2 Merck Sharp & Dohme LLC · Iowa City, Iowa and 9 other locations · NCT07700758

• Ifinatamab Deruxtecan in kids with relapsed or refractory solid cancers

  This study tests whether I-DXd can help children whose solid tumors have come back or not responded to previous treatments.

  Recruiting at 35 sites Phase 1/2 Merck Sharp & Dohme LLC · Los Angeles, California and 34 other locations · NCT07630974

• MK-4884 safety in advanced solid tumors

  This early-phase study tests different doses of MK-4884 to see if it is safe and tolerable for adults with certain advanced solid cancers.

  Recruiting at 10 sites Phase 1 Merck Sharp & Dohme LLC · St Louis, Missouri and 9 other locations · NCT07600749

• ICVAX therapeutic DNA vaccine for people living with HIV in Hong Kong

  This trial tests whether the ICVAX DNA vaccine, given with three different delivery devices, is safe and boosts HIV-specific T-cell responses in adults on stable antiretroviral therapy.

  Recruiting Phase 1 Yicura Holding (HK) Limited · Shatin, New Territories · NCT07530198

• AIC263029 in kidney transplant recipients with BK virus infection

  This trial tests whether AIC263029 is safe and tolerable and can lower BK virus levels in adults who recently had a kidney transplant and have BK viremia, compared with placebo.

  Recruiting at 14 sites Phase 2 AiCuris Anti-infective Cures AG · Birmingham, Alabama and 13 other locations · NCT07503561

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.